190 related articles for article (PubMed ID: 33101610)
21. Influence of Chemokine N-Terminal Modification on Biased Agonism at the Chemokine Receptor CCR1.
Sanchez J; Lane JR; Canals M; Stone MJ
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096719
[TBL] [Abstract][Full Text] [Related]
22. Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins.
Iacovelli L; Felicioni M; Nisticò R; Nicoletti F; De Blasi A
Neuropharmacology; 2014 Feb; 77():303-12. PubMed ID: 24148810
[TBL] [Abstract][Full Text] [Related]
23. Cross-communication between G
Navarro G; Cordomí A; Brugarolas M; Moreno E; Aguinaga D; Pérez-Benito L; Ferre S; Cortés A; Casadó V; Mallol J; Canela EI; Lluís C; Pardo L; McCormick PJ; Franco R
BMC Biol; 2018 Feb; 16(1):24. PubMed ID: 29486745
[TBL] [Abstract][Full Text] [Related]
24. A2A adenosine-receptor-mediated facilitation of noradrenaline release in rat tail artery involves protein kinase C activation and betagamma subunits formed after alpha2-adrenoceptor activation.
Fresco P; Oliveira JM; Kunc F; Soares AS; Rocha-Pereira C; Gonçalves J; Diniz C
Neurochem Int; 2007 Jul; 51(1):47-56. PubMed ID: 17493708
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of endogenous A
Goulding J; May LT; Hill SJ
Biochem Pharmacol; 2018 Jan; 147():55-66. PubMed ID: 29106905
[TBL] [Abstract][Full Text] [Related]
26. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes.
Link AA; Kino T; Worth JA; McGuire JL; Crane ML; Chrousos GP; Wilder RL; Elenkov IJ
J Immunol; 2000 Jan; 164(1):436-42. PubMed ID: 10605040
[TBL] [Abstract][Full Text] [Related]
27. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.
Azzi M; Charest PG; Angers S; Rousseau G; Kohout T; Bouvier M; Piñeyro G
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11406-11. PubMed ID: 13679574
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
29. Adenosine activates Gα
Arizmendi N; Kulka M
Biochem Pharmacol; 2018 Oct; 156():157-167. PubMed ID: 30099007
[TBL] [Abstract][Full Text] [Related]
30. Reactive oxygen species are required for β2 adrenergic receptor-β-arrestin interactions and signaling to ERK1/2.
Singh M; Moniri NH
Biochem Pharmacol; 2012 Sep; 84(5):661-9. PubMed ID: 22728070
[TBL] [Abstract][Full Text] [Related]
31. Structural mechanism of GPCR-arrestin interaction: recent breakthroughs.
Park JY; Lee SY; Kim HR; Seo MD; Chung KY
Arch Pharm Res; 2016 Mar; 39(3):293-301. PubMed ID: 26825061
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations.
Wingler LM; Elgeti M; Hilger D; Latorraca NR; Lerch MT; Staus DP; Dror RO; Kobilka BK; Hubbell WL; Lefkowitz RJ
Cell; 2019 Jan; 176(3):468-478.e11. PubMed ID: 30639099
[TBL] [Abstract][Full Text] [Related]
33. Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential.
Seyedabadi M; Ghahremani MH; Albert PR
Pharmacol Ther; 2019 Aug; 200():148-178. PubMed ID: 31075355
[TBL] [Abstract][Full Text] [Related]
34. Molecular dynamics simulation of biased agonists at the dopamine D2 receptor suggests the mechanism of receptor functional selectivity.
Montgomery D; Campbell A; Sullivan HJ; Wu C
J Biomol Struct Dyn; 2019 Aug; 37(12):3206-3225. PubMed ID: 30124143
[TBL] [Abstract][Full Text] [Related]
35. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils.
Gabl M; Holdfeldt A; Sundqvist M; Lomei J; Dahlgren C; Forsman H
Biochem Pharmacol; 2017 Dec; 145():114-122. PubMed ID: 28855087
[TBL] [Abstract][Full Text] [Related]
36. A carboxyl-terminally truncated mutant and nonglycosylated A2a adenosine receptors retain ligand binding.
Piersen CE; True CD; Wells JN
Mol Pharmacol; 1994 May; 45(5):861-70. PubMed ID: 8190103
[TBL] [Abstract][Full Text] [Related]
37. Role of extracellular cysteine residues in the adenosine A2A receptor.
De Filippo E; Namasivayam V; Zappe L; El-Tayeb A; Schiedel AC; Müller CE
Purinergic Signal; 2016 Jun; 12(2):313-29. PubMed ID: 26969588
[TBL] [Abstract][Full Text] [Related]
38. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
[TBL] [Abstract][Full Text] [Related]
39. Human Adenosine A
Carpenter B; Lebon G
Front Pharmacol; 2017; 8():898. PubMed ID: 29311917
[TBL] [Abstract][Full Text] [Related]
40. Signaling via A2A adenosine receptor in four PC12 cell clones.
Arslan G; Kull B; Fredholm BB
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):28-32. PubMed ID: 9933147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
